Johnson & Johnson (NYSE:JNJ) PT Raised to $152.00

Johnson & Johnson (NYSE:JNJ) had its price objective upped by Credit Suisse Group from $149.00 to $152.00 in a research note published on Wednesday, October 17th. They currently have an outperform rating on the stock.

Several other brokerages have also recently issued reports on JNJ. Goldman Sachs Group raised shares of Johnson & Johnson from a sell rating to a neutral rating in a report on Thursday, July 12th. Wells Fargo & Co reaffirmed an outperform rating and issued a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. Raymond James lifted their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an outperform rating in a report on Wednesday, October 17th. ValuEngine raised shares of Johnson & Johnson from a sell rating to a hold rating in a report on Saturday, July 28th. Finally, Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They issued a market perform rating and a $129.00 target price for the company. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $142.54.

NYSE:JNJ traded up $0.04 during mid-day trading on Wednesday, hitting $145.34. 5,343,128 shares of the company’s stock were exchanged, compared to its average volume of 7,921,995. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The firm has a market capitalization of $388.35 billion, a P/E ratio of 18.21, a PEG ratio of 2.26 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. Johnson & Johnson’s quarterly revenue was up 3.6% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Ronald A. Kapusta sold 8,441 shares of the company’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the sale, the chief accounting officer now directly owns 17,284 shares of the company’s stock, valued at $2,508,772.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,340 shares of company stock valued at $11,992,396. 0.22% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. DDD Partners LLC lifted its position in Johnson & Johnson by 0.5% during the third quarter. DDD Partners LLC now owns 67,595 shares of the company’s stock valued at $9,340,000 after purchasing an additional 350 shares during the last quarter. PDS Planning Inc lifted its position in Johnson & Johnson by 10.8% during the third quarter. PDS Planning Inc now owns 3,673 shares of the company’s stock valued at $507,000 after purchasing an additional 357 shares during the last quarter. San Francisco Sentry Investment Group CA lifted its position in Johnson & Johnson by 2.2% during the third quarter. San Francisco Sentry Investment Group CA now owns 16,986 shares of the company’s stock valued at $2,347,000 after purchasing an additional 358 shares during the last quarter. Trust Department MB Financial Bank N A lifted its position in Johnson & Johnson by 0.4% during the third quarter. Trust Department MB Financial Bank N A now owns 98,938 shares of the company’s stock valued at $13,670,000 after purchasing an additional 363 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its position in Johnson & Johnson by 3.0% during the third quarter. Global Retirement Partners LLC now owns 12,394 shares of the company’s stock valued at $1,712,000 after purchasing an additional 365 shares during the last quarter. Institutional investors and hedge funds own 66.60% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Hedge Funds Explained

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply